Melanotan Peptides as Potential Therapeutics in Parkinson’s Disease

Abstract

Parkinson’s disease features progressive substantia nigra dopaminergic neuron loss in a metal-rich, pro-oxidant milieu. Neuromelanin buffers redox-active metals such as iron and copper, yet can become iron-saturated in Parkinson’s disease, increasing labile metal pools and oxidative injury. Neuromelanin composition is also relevant: pheomelanin-enriched pigment is associated with weaker metal chelation and greater oxidative burden than eumelanin-rich pigment. This paper evaluates melanocortin 1 receptor (MC1R) agonism, using melanotan I (afamelanotide, NDP-α-MSH) and melanotan II as exemplars, as a metallomics-informed strategy to modify disease biology. We propose that MC1R activation could bias pigment chemistry toward a more eumelanin-like profile, expand effective metal sequestration capacity, and reduce iron-driven lipid peroxidation and ferroptosis susceptibility. MC1R signaling may also dampen neuroinflammatory programs that amplify neurodegeneration. These mechanisms define testable translational endpoints for preclinical and clinical evaluation.

KEYWORDS

Parkinson’s disease, metallomics, MC1R, melanotan, afamelanotide, neuromelanin, iron sequestration, oxidative stress, ferroptosis, neuroinflammation

Overview

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta. While its etiology is multifactorial, a growing body of evidence suggests a metal-driven framework, where dysregulated metal homeostasis is a central pathological feature [1, 2]. This dysregulation can lead to iron-dependent cell death (ferroptosis) and is intertwined with gut dysbiosis and α-synuclein pathology [2]. Neuromelanin, the dark pigment within dopaminergic neurons, plays a critical role in this process, acting as a buffer by sequestering redox-active metals, such as iron [3]. However, in PD, this buffering capacity can be overwhelmed, leading to a toxic labile iron pool that fuels oxidative stress [3].

A compelling epidemiological link between PD and melanoma, a cancer of pigment-producing melanocytes, highlights the role of the melanocortin 1 receptor (MC1R), a key regulator of melanin synthesis [4]. Loss-of-function MC1R variants, prevalent in individuals with red hair, are associated with an increased risk for both diseases. This is not merely a cosmetic correlation but a mechanistic one; these variants shift pigment production from the dark, neuroprotective eumelanin to the reddish, pro-oxidant pheomelanin [1, 4]. This pheomelanin-rich composition compromises neuromelanin’s ability to safely sequester metals, effectively lowering the threshold for iron-driven neurotoxicity [1]. Recent findings confirm that neuromelanin in PD brains is abnormally enriched with these pheomelanin-like subunits, exacerbating oxidative damage [5].

This convergence of evidence, from microbial metallomics to the genetics of pigmentation, suggests that modulating MC1R activity is a viable therapeutic strategy. By promoting the synthesis of neuroprotective eumelanin and leveraging the receptor’s known anti-inflammatory and cell-protective signaling pathways [6, 7], MC1R agonists such as melanotan peptides offer a compelling, disease-modifying potential to mitigate neurodegeneration.

MC1R Activation and Eumelanin Synthesis

Melanotan I (afamelanotide) and II are analogues of α-melanocyte-stimulating hormone (α-MSH) that activate the melanocortin 1 receptor (MC1R). MC1R signaling in pigment-producing cells drives melanin synthesis, particularly shifting production toward eumelanin (dark, UV-protective pigment) over pheomelanin (reddish pigment)[3, 4, 5]. Individuals with functional MC1R (“non-redhead” variants) produce predominantly eumelanin, whereas loss-of-function MC1R variants (common in red-haired individuals) lead to higher pheomelanin levels[3, 4, 5]. Eumelanin is generally considered an antioxidant pigment, whereas pheomelanin can generate oxidative stress under certain conditions[3, 4, 5]. Thus, MC1R activation by melanotan is expected to increase eumelanin synthesis, mirroring the tanning response seen in skin (increased dark pigmentation)[3, 4, 5]. This mechanism is central to the hypothesis that melanotan could beneficially alter pigment production in cells beyond the skin, potentially including neuromelanin in the brain.

Eumelanin’s Metal Sequestration and Oxidative Stress

Eumelanin has a strong capacity to chelate and sequester redox-active metal ions, such as iron and copper, which can otherwise catalyze harmful free-radical reactions [4, 6]. By binding these metals, eumelanin helps reduce the labile iron pool and mitigates oxidative stress in pigmented tissues[4, 6]. In contrast, pheomelanin (which contains sulfur) binds metals less effectively and can even promote oxidative stress by redox-cycling metals[4, 6]. This difference is well illustrated in recent findings on neuromelanin (the pigment in brain dopaminergic neurons): neuromelanin contains both eumelanin and pheomelanin subunits, and the latter is associated with compromised metal-binding and increased oxidative stress[4, 6]. Increasing the fraction of eumelanin (through MC1R stimulation) could therefore enhance metal chelation in tissues, lowering oxidative damage. Essentially, eumelanin acts as a protective antioxidant and metal sink, whereas pheomelanin is a weaker chelator and may contribute to oxidative injury[4, 6].

Neuromelanin in the Substantia Nigra and Ferroptosis

Dopaminergic neurons in the substantia nigra pars compacta synthesize neuromelanin, a dark polymer pigment similar to melanin, as a byproduct of dopamine metabolism. Neuromelanin is thought to play a protective role in these neurons by sequestering excess iron and other heavy metals. In normal aging, neuromelanin gradually accumulates iron, zinc, copper, and other metals in an inert complex[6]. By locking away redox-active iron, neuromelanin can shield neurons from iron-mediated oxidative stress – including processes like ferroptosis, an iron-dependent form of cell death caused by lipid peroxidation. Neuromelanin and ferritin together serve as an “iron well” in the substantia nigra, keeping free iron levels low[6]. In Parkinson’s disease (PD), however, this balance is disturbed: neuromelanin becomes iron-saturated, and its binding capacity is exceeded, leading to spillover of free iron and generation of toxic radicals[6]. Post-mortem studies show elevated labile iron in the substantia nigra, along with the loss of neuromelanin-rich neurons [6]. The iron overload in PD neurons contributes to oxidative damage and may trigger ferroptotic death pathways. Thus, neuromelanin is a double-edged sword: in healthy neuron,s it confers protection by sequestering iron, but when overwhelmed or when neurons die (releasing neuromelanin and bound iron), it can contribute to oxidative neurodegeneration. Enhancing neuromelanin’s capacity or preserving its integrity could theoretically protect dopaminergic neurons from iron-induced injury.

Enhancing Neuromelanin via MC1R Agonism

Given neuromelanin’s protective metal-binding role, a compelling idea is to boost neuromelanin content or alter its composition toward eumelanin as a neuroprotective strategy. Activating MC1R in dopaminergic neurons (or supportive cells) via melanotan might promote pathways that favor eumelanin-like pigment production within neuromelanin. Notably, recent research has found that in PD patients’ substantia nigra, neuromelanin is abnormally enriched in pheomelanin subunits (DOPA-derived pheomelanin) and relatively deficient in eumelanin, compared to controls[4, 7]. This pheomelanin-rich neuromelanin in PD is associated with increased oxidative stress and toxicity. Synthetic pheomelanin analogues have been shown to cause neuronal cell death in vitro, whereas synthetic eumelanin has not[4, 7]. These findings suggest that shifting neuromelanin toward a more eumelanin-rich state may be protective [4, 7]. By activating MC1R, melanotan might tilt pigment synthesis pathways to favor eumelanin (as it does in melanocytes), potentially increasing the iron-binding capacity of neuromelanin and reducing the pool of free iron within substantia nigra neurons. This could, in theory, lower ongoing oxidative damage and risk of ferroptosis in those cells. Researchers have identified melanin composition as a potential therapeutic target in PD [4, 7]. It’s important to note that dopaminergic neurons do express MC1R to some extent[4, 7], so a CNS-penetrant MC1R agonist could directly act on these neurons to influence neuromelanin production. While it is not yet proven that melanotan can substantially increase neuromelanin content in vivo, the concept is biologically plausible given MC1R’s role in pigmentation. Even a modest increase in neuromelanin or an improved eumelanin: pheomelanin ratio might enhance the pigment’s metal-sequestration function, thereby reducing toxic labile iron accumulation in PD-affected neurons.

Neuroprotective and Anti-Inflammatory Effects of MC1R Agonists

Beyond pigment synthesis, MC1R activation triggers cell-protective and anti-inflammatory pathways that could benefit dopaminergic neurons. There is growing in vivo evidence linking MC1R stimulation (including by melanotan analogues) to neuroprotection in Parkinsonian models:

Genetic and epidemiological links: Loss-of-function MC1R (“redhead”) variants have been associated with higher PD risk and earlier neurodegeneration. In mice carrying a redhead MC1R mutation, fewer dopamine neurons develop in the substantia nigra, and the mice show greater susceptibility to toxins that kill those neurons[3]. This suggests that basal MC1R signaling supports the survival of dopaminergic neurons. Consistently, the MC1R gene is expressed in substantia nigra dopamine neurons[3], and its activity appears to have a protective role.

α-Synuclein model: A 2022 study showed that activating MC1R protects against α-synuclein–induced toxicity[7]. Mice overexpressing a pathogenic α-synuclein in the substantia nigra had worse neurodegeneration if they carried an inactivated Mc1r gene, with more neuroinflammation and oxidative stress. In contrast, mice with normal MC1R signaling coped better[7]. Remarkably, treatment with MC1R agonist compounds rescued dopaminergic neurons from α-synuclein toxicity in these models[7]. The protective effect was accompanied by activation of the Nrf2 pathway (a master regulator of antioxidant responses), suggesting MC1R signaling upregulated cellular defense genes[7]. The same study confirmed that MC1R levels are lower in the substantia nigra of PD patients, hinting that the loss of MC1R activity may contribute to PD vulnerability [7]. Overall, this provides proof of concept that MC1R agonism (potentially via melanotan or similar drugs) can protect dopaminergic neurons in an aggressive PD model [7].

Inflammation and immune modulation: MC1R is also expressed on immune cells (microglia, macrophages, etc.), where its activation has anti-inflammatory effects. Peripheral administration of the MC1R agonist NDP-MSH (melanotan I) in an MPTP+LPS mouse model of PD dramatically reduced neuroinflammation and neuronal loss[8]. In this study, NDP-MSH did not cross the blood–brain barrier, yet it still preserved nigrostriatal neurons and motor function, likely by modulating peripheral and infiltrating immune cells[8]. Treated mice showed less microglial activation in the substantia nigra and lower levels of inflammatory cytokines (TNF-α, IL-1β) in the brain[8]. Interestingly, if regulatory T-cells were depleted, the neuroprotective effect was lost, indicating that MC1R agonism works in part by inducing an anti-inflammatory, neuroprotective immune environment [8]. These results underscore that MC1R agonists can indirectly shield neurons by dampening neuroinflammation. Given that chronic inflammation is implicated in the progression of PD, melanotan’s immunomodulatory action could be a valuable therapeutic approach.

In summary, multiple lines of evidence (genetic, toxin models, and inflammation models) converge on the idea that MC1R activation is neuroprotective in the context of Parkinson’s disease. Melanotan I/II, by acting as MC1R agonists, has shown potential to reduce dopaminergic neuron loss and neuroinflammation in preclinical studies [7, 8]. This provides a strong rationale to pursue these compounds (or related MC1R agonists) as disease-modifying therapies for PD.

Blood–Brain Barrier Penetration of Melanotan I vs II

A key pharmacokinetic consideration is whether melanotan peptides can cross the blood-brain barrier to exert direct effects on neurons. Melanotan I (afamelanotide) is a linear 13-amino-acid peptide (NDP-α-MSH) that is primarily active in peripheral tissues and skin. It has very limited ability to cross the blood–brain barrier (BBB)[8, 9]. In fact, afamelanotide was designed for peripheral action (e.g. increasing skin pigmentation) and is delivered as a controlled-release implant; it produces minimal central nervous system effects. Consistent with this, studies in mice found that systemically administered NDP-MSH was undetectable in the brain (intact BBB), yet still acted via peripheral MC1R to protect the nigrostriatal pathway[8, 9]. Thus, melanotan I does not penetrate the CNS to a significant extent.

Melanotan II, on the other hand, is a smaller, cyclic peptide (7 amino acids) and is known to cross the BBB and engage central melanocortin receptors[5]. This property is evidenced by its notable CNS-mediated side effects: melanotan II can cause loss of appetite and increased libido/erections by activating MC3/MC4 receptors in the brain[5]. Because it is non-selective and brain-penetrant, melanotan II can bind MC4 receptors in the hypothalamus (suppressing appetite) and MC3/MC4 in sexual function centers[5]. These CNS effects indicate that a substantial portion of a melanotan II dose reaches central receptors. For therapy of PD, CNS penetration is a double-edged sword. On one hand, a brain-penetrant MC1R agonist might directly stimulate neuromelanin production and neuronal survival pathways in substantia nigra neurons – a potential advantage over melanotan I. On the other hand, melanotan II’s ability to cross the BBB comes with off-target activation of other melanocortin receptors, leading to systemic and neurological side effects (fatigue, nausea, blood pressure changes, etc., in addition to appetite and sexual effects)[5].

In a translational context, one might consider using melanotan I for primarily peripheral actions (immunomodulation, reducing inflammation) and melanotan II (or similar analog) for central actions (directly affecting neurons). Alternatively, developing a selective MC1R agonist that crosses the BBB but avoids MC4R activation could be ideal – this is an area of ongoing medicinal chemistry research (e.g., dersimelagon is an oral MC1R-selective agonist in development for skin disease[5]. However, its CNS penetrance is not yet clear. In summary, melanotan II has the pharmacokinetic edge of brain accessibility[5], but melanotan I may require innovative delivery strategies (intranasal, higher dosing, or disruption of the BBB) to affect the CNS meaningfully. The choice between them would hinge on balancing the need for central efficacy with the risk of side effects from widespread receptor activation.

Therapeutic Feasibility, Dosing, and Safety Profile

Dosing and delivery: Afamelanotide (Melanotan I) is currently administered as a 16 mg subcutaneous implant every 2 months for patients with erythropoietic protoporphyria. For chronic neurodegenerative use, more frequent dosing or alternate routes might be needed to maintain consistent MC1R activation. Melanotan II, typically used as an injectable in research or “tanning” contexts, has a shorter half-life (~1–2 hours)[9]. Chronic PD therapy might require daily injections or infusion of melanotan II, unless a longer-acting formulation is developed. The practicality of frequent injections and patient adherence would need consideration, especially for older PD patients. An implant formulation (analogous to afamelanotide’s) could improve convenience if adapted for melanotan II or another analog.

Safety and side effects: Both melanotan peptides cause significant physiological effects that must be weighed against their potential benefits in PD:

Pigmentation: By design, melanotans increase melanin production in the skin, causing a tanning effect and even darkening of moles or freckles. While mostly cosmetic, this effect requires monitoring because there have been case reports (mostly with unregulated melanotan II use) of melanoma emerging after usage[5]. It’s unclear if melanotan directly promotes melanoma or simply darkens pre-existing lesions. Still, PD patients (who already have a higher baseline melanoma risk than the general population) would need regular dermatological screenings if on these drugs. The long-term cancer risk from chronic melanotan use remains an open question, though afamelanotide’s clinical use so far has not shown significant melanoma incidence under controlled conditions.

Cardiovascular and autonomic effects: Melanotan II’s activation of central MC3/MC4 receptors can lead to reduced appetite, nausea, and gastrointestinal upset in many users[5, 10]. Nausea is, in fact, one of the most common acute side effects. Flushing, transient fatigue or lightheadedness, and increases in blood pressure or heart rate have also been reported anecdotally. These effects may be dose-dependent and tend to subside after the first few doses as tolerance develops. In a PD population, weight loss due to appetite suppression could be problematic (since PD patients often already lose weight), and nausea could worsen quality of life or complicate medication regimens. Careful dose titration would be needed to minimize these effects. Melanotan I, being peripherally focused, causes far less appetite suppression and central side effects; its main side effects are skin tanning and occasional nausea/headache [5, 10].

Sexual effects: Melanotan II is notorious for causing spontaneous penile erections in men (and sometimes increased sexual arousal in women) because of MC4 receptor stimulation in the brain. While this has even been explored as a therapy for erectile dysfunction, in the context of PD, it could be an unwanted side effect or safety concern (e.g., triggering priapism in rare cases[9]). PD patients, especially older ones or those on certain medications, might be vulnerable to cardiovascular strain from such effects. Melanotan I does not have this issue, as it does not significantly cross the blood-brain barrier [9].

Despite these side effects, it’s worth noting that afamelanotide has shown a generally good safety profile in long-term use. In an 8-year observational study with over 100 EPP patients (cumulatively over 1000 implants), only minor adverse events (mainly transient nausea) were attributed to the drug, and no serious toxicity emerged[10]. Patients maintained treatment for years with high compliance, suggesting chronic melanotan I therapy can be tolerable with appropriate monitoring[10]. This is encouraging for the feasibility of long-term use in a condition like PD, provided the risk–benefit balance is favorable. Melanotan II lacks equivalent long-term safety data, as it’s not an approved medication; however, short-term studies and off-label experience indicate that vigilant dose management can mitigate some side effects, and most are reversible upon discontinuation of the drug.

Risk–benefit analysis: The central question is whether melanotan’s potential to slow neurodegeneration (by enhancing neuromelanin and reducing oxidative/inflammatory damage) outweighs its side effect burden. If robust neuroprotective effects seen in animal models translate to humans – for example, if melanotan could significantly preserve substantia nigra neurons and slow PD progression – this would represent a major therapeutic advance, as current PD medications do not prevent neuron loss. In that scenario, side effects such as mild nausea, cosmetic tanning, or manageable appetite changes might be acceptable trade-offs. However, if the benefits are marginal, the risks (especially anything that might increase melanoma risk or cardiovascular strain) would loom larger.

A practical compromise might involve targeted dosing strategies. For instance, using melanotan I to leverage its peripheral anti-inflammatory benefits (as demonstrated by reduced microglial activation and cytokines[5, 8]) in early PD, and only using a CNS-penetrant analog for patients who can tolerate it or who have rapid progression that warrants aggressive intervention. Additionally, alternative MC1R agonists (e.g. small molecules or selective peptides) could be developed to minimize off-target effects. This is an active area of research given MC1R’s role in other conditions as well[5, 8].

Conclusion

In conclusion, melanotan I and II present a novel and intriguing approach to PD modification by boosting a natural neuronal defense (neuromelanin) and taming neuroinflammation, thereby addressing key pathogenic factors such as iron-driven oxidative stress and microglial activation. The mechanistic rationale is supported by multiple studies [4, 7, 8], but real-world therapeutic use would require careful consideration of pharmacology and safety. Further research – including in vitro studies on neuromelanin synthesis and in vivo trials in PD models or patients – is needed to determine if the eumelanin-enhancing, iron-sequestering strategy can deliver clinically meaningful neuroprotection. If feasible, melanotan or next-generation MC1R agonists could be repurposed as disease-modifying agents in Parkinson’s disease, marking a shift from simply treating symptoms to altering the neurochemical environment (more eumelanin, less free iron and inflammation) that underlies neuronal survival. The path forward would involve rigorous clinical trials to assess the neuroprotective efficacy versus side effects in PD patients – a challenge worth undertaking, given the current lack of disease-modifying therapies.

References

^[1]1. Eyer, K., & Pendergrass, K. (2025). Pheomelanin, Eumelanin, and Neuromelanin: A Metal-Linked Hypothesis for Parkinson’s Risk in Redheads. Zenodo. https://doi.org/10.5281/zenodo.17976306

^[x] 2. Pendergrass, K. (2025). Microbial Metallomics and Parkinson’s Disease: A Unified Metal-Driven Framework Linking Ferroptosis, Dysbiosis, and α-Synuclein Pathology. Zenodo. https://doi.org/10.5281/zenodo.17830083

^[x] 3. Duță C, Muscurel C, Dogaru CB, Stoian I. Ferroptosis, A Shared Mechanism for Parkinson’s Disease and Type 2 Diabetes. International Journal of Molecular Sciences. 2024; 25(16):8838. https://doi.org/10.3390/ijms25168838

^[x]4. Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked “redhead” MC1R influences dopaminergic neuron survival. Ann Neurol. 2017 Mar;81(3):395-406. doi: 10.1002/ana.24852.

^[x] 5. Cai W, Wakamatsu K, Zucca FA, Wang Q, Yang K, Mohamadzadehonarvar N, Srivastava P, Tanaka H, Holly G, Casella L, Ito S, Zecca L, Chen X. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease. Prog Neurobiol. 2023 Apr;223:102414. doi: 10.1016/j.pneurobio.2023.102414

^[x] 6. Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease. Mol Neurodegener. 2022 Feb 23;17(1):16. doi: 10.1186/s13024-022-00520-4

^[x] 7. Srivastava P, Nishiyama S, Lin SH, Srivastava A, Su C, Peng W, Levy M, Schwarzschild M, Xu Y, Chen X. Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson’s disease. Res Sq [Preprint]. 2023 Jun 12:rs.3.rs-3042571. doi: 10.21203/rs.3.rs-3042571/v1

^[x] 8. Böhm M, Robert C, Malhotra S, Clément K, Farooqi S. An overview of benefits and risks of chronic melanocortin-1 receptor activation. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):39-51. doi: 10.1111/jdv.20269

^[x] 9. Professional Monograph Melanotan II. Accessed December 20, 2025. https://peptidesociety.org/wp-content/uploads/2018/05/Melanotan-II-monograph-v2.docx.pdf

^[x] 10. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015 Jun;172(6):1601-1612. doi: 10.1111/bjd.13598

References

1. Pheomelanin, Eumelanin, and Neuromelanin: A Metal-Linked Hypothesis for Parkinson's Risk in Redheads.. Eyer, K., & Pendergrass, K.. (Zenodo. 2025.)